-+ 0.00%
-+ 0.00%
-+ 0.00%
Jingxin Pharmaceutical recently announced that according to the “Notice Concerning Issuance” issued by the National Health Insurance Administration and the Ministry of Human Resources and Social Security, the company's drug carripiperazine hydrochloride capsules passed the national medical insurance catalogue negotiations, and didacinib capsules were successfully renewed and included in the “National Drug Catalogue for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance”. Carripiperazine hydrochloride capsules are medical insurance class B, used to treat schizophrenia in adults. The agreement is valid from January 1, 2027 to December 31, 2028; didacinib capsules are medical insurance category B and are used for short-term treatment of patients with insomnia. The “National Health Insurance Catalogue” will be officially implemented on January 1, 2027, and will not have a significant impact on the company's current business performance for the time being.
Share
Listen to the news
Jingxin Pharmaceutical recently announced that according to the “Notice Concerning Issuance” issued by the National Health Insurance Administration and the Ministry of Human Resources and Social Security, the company's drug carripiperazine hydrochloride capsules passed the national medical insurance catalogue negotiations, and didacinib capsules were successfully renewed and included in the “National Drug Catalogue for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance”. Carripiperazine hydrochloride capsules are medical insurance class B, used to treat schizophrenia in adults. The agreement is valid from January 1, 2027 to December 31, 2028; didacinib capsules are medical insurance category B and are used for short-term treatment of patients with insomnia. The “National Health Insurance Catalogue” will be officially implemented on January 1, 2027, and will not have a significant impact on the company's current business performance for the time being.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending